209 related articles for article (PubMed ID: 37528446)
1. Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide.
Khodakarami A; Kashani MA; Nazer A; Kheshti AM; Rashidi B; Karpisheh V; Masjedi A; Abolhasani S; Izadi S; Bagherifar R; Hejazian SS; Mohammadi H; Movassaghpour A; Feizi AAH; Hojjat-Farsangi M; Jadidi-Niaragh F
Cell Commun Signal; 2023 Aug; 21(1):188. PubMed ID: 37528446
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of apoptosis in B-cell chronic lymphocytic leukemia cells after treatment with all-trans retinoic acid in combination with interleukin-21 and rituximab.
Abbaszadeh-Goudarzi K; Shokri F; Hosseini M; Jadidi-Niaragh F; Ghalamfarsa G; Saboor-Yaraghi AA
J Cancer Res Ther; 2016; 12(4):1278-1283. PubMed ID: 28169240
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia.
Wu RP; Hayashi T; Cottam HB; Jin G; Yao S; Wu CC; Rosenbach MD; Corr M; Schwab RB; Carson DA
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7479-84. PubMed ID: 20368435
[TBL] [Abstract][Full Text] [Related]
7. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
8. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia.
McMahon KM; Scielzo C; Angeloni NL; Deiss-Yehiely E; Scarfo L; Ranghetti P; Ma S; Kaplan J; Barbaglio F; Gordon LI; Giles FJ; Thaxton CS; Ghia P
Oncotarget; 2017 Feb; 8(7):11219-11227. PubMed ID: 28061439
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
11. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
[TBL] [Abstract][Full Text] [Related]
12. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
13. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Hillmen P
Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
[TBL] [Abstract][Full Text] [Related]
14. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
[TBL] [Abstract][Full Text] [Related]
15. Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
Borsky M; Hrabcakova V; Novotna J; Brychtova Y; Doubek M; Panovska A; Muller P; Mayer J; Trbusek M; Mraz M
Leuk Res; 2021 Dec; 111():106684. PubMed ID: 34438120
[TBL] [Abstract][Full Text] [Related]
16. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of NKCD56bright cells in monitoring the progression of chronic lymphocytic leukemia during treatment.
Blachnio K; Grygalewicz B; Woroniecka R; Rygier J; Pienkowska-Grela B; Rymkiewicz G; Kawiak J
Folia Histochem Cytobiol; 2022; 60(3):203-214. PubMed ID: 36045602
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
19. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
20. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia.
Prezma T; Shteinfer A; Admoni L; Raviv Z; Sela I; Levi I; Shoshan-Barmatz V
Cell Death Dis; 2013 Sep; 4(9):e809. PubMed ID: 24052077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
